News | July 27, 2012

Real-time Imaging and Tracking Means Safer Radiation Therapy for Patients

July 27, 2012 — Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso System featuring GPS for the Body technology and Beacon electromagnetic transponders for patients with certain types of cancer. This new technology provides accurate, precise and real-time tracking to keep radiation focused on the tumor resulting in fewer side effects and a better quality of life for the patient.

Using miniaturized, non-ionizing, non-radioactive implanted devices called Beacon transponders, the Calypso System continuously and accurately tracks the location of cancerous tumors. For example, these rice-sized Beacons are implanted into the prostate or prostatic bed during an outpatient procedure, and are then tracked with a 4-D localization and tracking system. If the prostate or tumor bed moves out of range during treatment, the radiation beam turns off until it comes back into range again.

The real-time position and motion information provided by the Calypso System offers objective reassurance that radiation treatment is delivered precisely to the prescribed target, not to surrounding healthy tissue.

While radiation to the pelvic area can affect urinary, bowel and sexual function, research has shown that patients treated with Calypso had significantly fewer side effects in bowel urgency and frequency, fecal incontinence and urinary irritation. They also had fewer sexual side effects. Calypso technology allows the radiation oncologist to safely and maximally cover cancerous areas while minimizing normal tissue exposure to radiation.

Studies have also shown that patients who have undergone the Calypso procedure versus other similar treatments, have lived longer, healthier lives. The Calypso's GPS for the Body is the only U.S. Food and Drug Administration (FDA)-approved technology to track tumors in real time. Calypso can be used in primary radiation treatment or as an adjunctive treatment to surgery.

For more information: www.virginiahospitalcenter.com

Related Content

Mevion Achieves CE Mark for S250i Proton Therapy System
News | Proton Therapy | November 21, 2017
November 21, 2017 — Mevion Medical Systems announced the Mevion S250i...
RayStation Selected for New Tennessee Proton Therapy Center
News | Treatment Planning | November 20, 2017
November 20, 2017 — Provision Healthcare has selected RayStation for external beam planning at the new Provision Care
Sponsored Content | Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Synthetic CT Images Suitable for Prostate Cancer Radiotherapy Planning
News | Treatment Planning | November 14, 2017
Spectronic Medical announced that new data for their MRIPlanner software, generating synthetic computed tomography (sCT...
ASTRO: CMS Report on Radiation Therapy Payment Model Charts Path to Value-Based Cancer Care
News | Radiation Therapy | November 08, 2017
The American Society for Radiation Oncology (ASTRO) called on the Centers for Medicare and Medicaid Services (CMS) to...
U.S. Recognizes Radiologic Technologists Nov. 5-11
News | Imaging | November 06, 2017
November 6, 2017 — During National Radiologic Technology Week (NRTW) every November, hospitals, healthcare centers an
Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust
News | Radiation Therapy | November 06, 2017
November 6, 2017 — Nearly one-third of women with...
Study shows tissue marker reduces radiation target volumes, produces many other advantages

These CT images show placement of a 3-D fixed array implanted fiducial (3-D marker) at the time of oncoplastic tumor resection. The original LCTV (LCTVo) was retrospectively re-contoured by the radiation oncologist (LCTVro) and breast surgeon (LCTVbs). Thereafter, both re-contours were combined to create the collaborative LCTV (LCTVc), which required agreement of both the radiation oncologist and breast surgeon. Volume differences between the original LCTV (LCTVo) and the collaborative LCTVc were then evaluated, and demonstrated a mean and median reduction in LCTV.

Feature | Tumor Tracking Systems | November 06, 2017 | By William Hall, M.D.
Radiation planning for breast cancer relies on accurate delineation of the post-lumpectomy target volume as identified...
PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy
News | Proton Therapy | November 01, 2017
Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy...
Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients
News | Proton Therapy | November 01, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional...
Overlay Init